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From Stock Bottle to Vaccine:
Elucidating the Particle Size
Distributions of Aluminum Adjuvants
Using Dynamic Light Scattering
Emma Shardlow, Matthew Mold and Christopher Exley *
Lennard-Jones Laboratories, The Birchall Centre, Keele University, Staffordshire, UK
The physicochemical properties of aluminum salts are key determinants of their resultant
adjuvanticity in vivo when administered as part of a vaccine. While there are links
between particle size and the efficacy of the immune response, the limited literature
directly characterizing the PSD of aluminum adjuvants has stymied the elucidation of
such a relationship for these materials. Hence, this comparative study was undertaken
to monitor the PSD of aluminum adjuvants throughout the process of vaccine formulation
using DLS. A significant proportion of the stock suspensions was highly agglomerated
(>9 µm) and Alhydrogel® exhibited the smallest median size (2677 ± 120 nm) in
comparison to Adju-Phos® or Imject alum® (7152 ± 308 and 7294 ± 146 nm
respectively) despite its large polydispersity index (PDI). Dilution of these materials
induced some degree of disaggregation within all samples with Adju-Phos® being the
most significantly affected. The presence of BSA caused the median size of Alhydrogel®
to increase but these trends were not evident when model vaccines were formulated with
either Adju-Phos® or Imject alum®. Nevertheless, Alhydrogel® and Adju-Phos® exhibited
comparable median sizes in the presence of this protein (4194 ± 466 and 4850 ± 501
nm respectively) with Imject alum® being considerably smaller (2155 ± 485 nm). These
results suggest that the PSD of aluminum adjuvants is greatly influenced by dilution and
the degree of protein adsorption experienced within the vaccine itself. The size of the
resultant antigen-adjuvant complex may be important for its immunological recognition
and subsequent clearance from the injection site.
Keywords: aluminum adjuvants, vaccine characterization, particle size, zeta potential, antigen-adjuvant complex
INTRODUCTION
Where vaccines contain recombinant antigens, which are typically weakly immunogenic in
their own right, it is often necessary to also include an adjuvant within the formulation
itself. Adjuvant compounds increase the efficacy and longevity of the immunological response
through potentiation and polarization, while having the advantage that they themselves are not
expected to be individually antigenic (Cox and Coulter, 1997; Gupta, 1998). Despite the recent
advances in vaccinology only a limited number of materials are currently used within clinical
immunizations and aluminum salts still remain the most popular (Reed et al., 2013), perhaps
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owing to their perceived superior safety record and low
production cost (Goldenthal et al., 1993; Lindblad, 2004). The
lack of cell-mediated immunopotentiation and associated weak
adjuvanticity of these materials (Grun and Maurer, 1989; Brewer
et al., 1996; Jordan et al., 2004), however, is increasingly
problematic for vaccinologists as are the numerous reports
of adverse reactions observed in individuals inoculated with
aluminum-containing vaccines (Gherardi et al., 2001; Shaw and
Petrick, 2009; Shoenfeld and Agmon-Levin, 2011). Nevertheless,
aluminum salts continue to provide an archetypal model for the
study of both immunological and mechanistic events following
immunization (Exley et al., 2010).
The degree of antigenic adsorption at the adjuvant colloidal
interface is generally regarded as a major contributor to
their adjuvanticity in biological systems and is thus an
important consideration in vaccine design (Gupta, 1998). Where
strong adsorption coefficients are observed either through
ligand exchange or favorable electrostatic interactions, enhanced
antigenic retention at the site of inoculation appears to be the
most probable outcome (Iyer et al., 2003, 2004; Noe et al., 2010).
This is particularly beneficial with regards to the subsequent
recognition and uptake of material by infiltrating phagocytes
(Mannhalter et al., 1985; Morefield et al., 2005), which in the
case of aluminum is required for the inflammasome-mediated
release of pro-inflammatory cytokines (Eisenbarth et al., 2008).
Adsorptive parameters, however, require careful optimization
and several studies have shown that the strength of antigenic
adsorption is in fact inversely proportional to the antibody
response mounted in vivo (Iyer et al., 2003; Hansen et al., 2007,
2009; Noe et al., 2010).
Of the many factors that are known to influence both protein
adsorption and the immunogenicity of vaccines, particle size
is the parameter that has received the least attention. There
is some evidence to suggest that the size of aggregates within
simulant vaccines is influenced by the extent of proteinaceous
adsorption experienced at the surface of the adjuvant material
(Morefield et al., 2005). Indeed, the authors revealed that
formulations where strong attractive associations were present
between vaccine components contained larger entities than those
lacking these interactions when administered into biological
fluid. Recent studies have also revealed that a small elevation
in the particle size of the native adjuvant significantly impedes
protein adsorption through a reduction in the adsorptive capacity
of the material, although this has only been demonstrated using
a single commercial preparation (Huang and Wang, 2014). A
limitation of these studies, however, is the lack of data comparing
the size of the antigen-complex with that of the adjuvant itself.
Furthermore, only a limited number of communications refer
directly to the size of native aluminum salts and the majority
of these report average core sizes obtained under the anhydrous
conditions of TEM (Burrell et al., 2000a; Harris et al., 2012; Shah
et al., 2014).
This study was therefore undertaken as a cross-comparative
insight into the hydrodynamic particle size distribution (PSD)
of aluminum adjuvants and how this parameter was influenced
upon exposure to the myriad environments associated with the
process of vaccine formulation.
EXPERIMENTAL
Materials
Stock solutions of the commercial adjuvants Alhydrogel R©
(aluminum oxyhydroxide) and Adju-Phos R© (aluminum
hydroxyphosphate) were obtained from Brenntag Biosector,
Denmark and contained 10.1 and 5 mg/mL Al respectively. A
research preparation (Imject alum R©) was procured from Pierce,
UK and contained 40mg/mL of aluminum and magnesium
hydroxide (ca 13.3 mg/mL Al). Bovine serum albumin (BSA)
was purchased from Sigma Aldrich, UK.
Formulation of Simulant Vaccines
Vaccine simulants without antigen were prepared from stock
adjuvant preparations which were diluted into physiological
saline (9 g/L) to achieve a final aluminum concentration of ca 250
µg/mL. The final adjusted pH of these preparations was 7± 0.1.
Model vaccines containing BSA were prepared from a stock
solution containing 1 mg/mL protein in physiological saline (pH
7± 0.1). Adjuvant stocks were added dropwise to saline solutions
containing ca 50 µg/mL BSA to achieve a final aluminum
concentration of ca 250 µg/mL and re-adjusted to pH 7 ± 0.1
using 0.1M NaOH.
Both simulants and model vaccines were subject to gentle
agitation using a magnetic stirrer at 25◦C for a period of 1 h in
order to allow the latter adequate time for protein adsorption to
occur before analysis.
Dynamic Light Scattering
Particle size characterization was performed via photon
correlation spectroscopy using a Zetasizer Nano ZS (Malvern
Instruments, UK) equipped with a 633 nm laser, which collected
scattered light at an angle of 173◦. Samples were introduced into
pre-rinsed polystyrene cuvettes and size determinations were
performed over a range of 0.6–10 µm at 25◦C. All samples had
an automatic attenuation setting of 5–7 and a count rate which
greatly exceeded that determined through the analysis of the
pre-filtered sodium chloride diluent (50 kcps).
A total of five measurements were made per sample replicate
and only measurements that generated a multimodal fit error
of <0.005 and a PDI < 0.7 were accepted to ensure the quality
of the data collected (exclusive of data obtained for native
adjuvant stocks). The average of these measurements was used
to derive the size distribution values represented in the following
experimental figures.
The hydrodynamic size of particles (Dh) was determined
through the application of the Stokes-Einstein equation
(Equation 1), where the translational diffusion coefficient (D)
defines the velocity of random movement (Brownian motion)
experienced via particulate components of the system.
Dh = kT/3piηD (1)
The instrumentation generated two intensity based measures of
size: One derived from a cumulant algorithm (Z-average) and
another from a non-negative least squares fit of the correlation
function (size distribution). Due to the multimodality of the
size distributions obtained only the latter was used as part of
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the analysis. Despite the maximum limit of the instrumentation
being specified as 10 µm, the distribution analysis is only capable
of detecting particles up to ca 9 µm in size. As a consequence this
value will be used as the upper maximum in the following results
section.
Zeta Potential Measurements
Zeta potential characterization was performed via electrophoretic
light scattering using the same instrumentation as that used
for the determination of particle size. Samples were introduced
into polystyrene folded capillary cells containing gold plated
beryllium/copper electrodes and five measurements were made
per sample replicate.
Transmission Electron Microscopy (TEM)
Vaccine preparations visualized by TEM were subject to the
following protocol optimized byMold et al. (2013). Samples were
prepared upon pre-coated S162 200 mesh formvar/carbon coated
copper grids (Agar Scientific, UK).
Grids were prepared through immersion in a 30 µL bead of
freshly prepared sample for 2 mins, passed through ultrapure
water, wicked and stained with 2% w/v uranyl acetate (in 70% v/v
ethanol) for 30 s. Following staining, grids were re-wicked, passed
through ultrapure water and placed into 30 µL 30% v/v ethanol
for 30 s. Grids were finally re-wicked, covered and allowed to dry
for up to 24 h, prior to analysis via TEM. Each grid was visualized
using a JEOL1230 transmission electron microscope (operating
voltage–100 kV) with a Megaview III digital camera attachment
from Soft Imaging Systems (SIS). Captured images were analyzed
using iTEM universal TEM imaging platform software.
Statistical Analysis
Statistical analysis of the data was performed using GraphPad
Prism software (v.7). Multiple comparisons were performed
using ANOVA followed by Tukey post-hoc tests where data
satisfied tests for normality (Shapiro-Wilk where p ≥ 0.05).
Datasets which violated these assumptions were analyzed using
Kruskal-Wallis test followed by Dunn post-hoc tests. Pairwise
comparisons were made using two-tailed unpaired t-tests or
Mann–Whitney U-tests if normality assumptions were violated.
A p value of ≤ 0.05 was accepted as statistically significant.
RESULTS
The PSD and Zeta Potential of Native
Aluminum Adjuvants
In its native form, Alhydrogel R© generated a broad monomodal
distribution spanning ca 955–7456 nm with the majority of
the scattering intensity being detected between ca 2.2–3.3 µm
(Figure 1A). Meanwhile, the size distributions of Adju-Phos R© &
Imject alum R© were characterized by several discrete populations
between ca 100 and 8635 nm (Figure S1A) with those exhibiting
the greatest scattering intensities located toward the maximum
limit of the instrumentation. Relative comparisons inferred
that the median size of Alhydrogel R© particles was significantly
smaller than either Adju-Phos R© or Imject alum R© (2677 ± 120,
7152 ± 308, and 7294 ± 146 nm respectively, P ≤ 0.0001);
however, the PDI of the commercial adjuvants was consistently
high and thus compromised the validity of this data (Figure 1D).
Interrogation of the correlation coefficients obtained for each
material also revealed a tendency toward sedimentation as
demonstrated by the presence of spikes during the latter stages of
photonic decay (Figure S1C). These observations were consistent
with the concomitant detection of large fractions of material
which were out of range of the instrumentation (ca 36, 51, and
95% respectively).
In order to mitigate the issues experienced when analyzing
the native materials, adjuvants were diluted to 1 mg/mL Al
using ultrapure water. In all cases, reducing the concentration
of aluminum within samples practically abolished non-random
sedimentation events (Figure S1D) and increased the amount of
particles within range of the instrumentation to >93%. The PDI
of Alhydrogel R© and Adju-Phos R© was also reduced from 1 ± 0
and 0.86 ± 0.07 to 0.20 ± 0.02 and 0.19 ± 0.02 respectively.
Dilution prompted a decrease in the median size of all adjuvants
studied (1257 ± 54, 2054 ± 68, and 3633 ± 690 nm, P = 0.0079,
≤0.0001, and 0.0052 respectively) and this was most evident in
the case of Adju-Phos R© whose d50 value decreased to reflect
that obtained for Alhydrogel R© (P = 0.10) (Figure 1B and Figure
S1B). Imject alum R©, however, remained significantly larger than
Alhydrogel R© under these conditions (P = 0.0043) but similar in
size to Adju-Phos R© (P = 0.87).
Alhydrogel R© was positively charged in its native form (10.96
± 0.50 mV) while Adju-Phos R© and Imject alum R© were both
negatively charged, although the latter was closer to neutral
(−22.80 ± 3.07 and −0.07 ± 0.38 mV respectively) (Figure 1C).
The zeta potential of both Adju-Phos R© and Imject alum R©
decreased upon dilution and the former experienced the greatest
shift in magnitude with regards to charge (−38.37 ± 0.52
and −7.47 ± 0.15 mV, P = 0.0065 and 0.0079 respectively).
By contrast, Alhydrogel R© experienced a small but significant
increase in zeta potential under these conditions (13.63 ± 0.78
mV, P = 0.0079).
The Influence of Dilution into Saline upon
the PSD and Zeta Potential of Aluminum
Adjuvants
The dilution of Alhydrogel R© into saline produced a bimodal
distribution (Figure S2A) where the majority of scattering was
located between 2.6 and 3.2µm in size (Figure 2A). No difference
was observed between the median size of the distribution relative
to that observed for the native material (2875 ± 127 nm, P =
0.29) despite a noticeable increase in the percentage of detectable
particulates (>93%). In comparison to the 1 mg/mL Al solution,
however, the d50 value of this vaccine simulant was significantly
greater in magnitude (P = 0.0079) and an increase in PDI was
also noted (0.45± 0.059, P = 0.012).
The PSD of Adju-Phos R© and Imject alum R© also exhibited
bimodality within this electrolytic environment and the median
size of both adjuvants was dramatically reduced when compared
to their respective native stocks (4411± 128 and 2361± 423 nm,
P = 0.0003 and 0.0001 respectively). The amount of material in
range of the sizer also increased to >91 and >93% respectively.
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FIGURE 1 | Particle size distributions generated for native aluminum adjuvants (A) and those diluted to 1 mg/mL Al in UPW (B). Box plots are representative
of the interquartile range of the data while red dashed lines indicate the maxima and minima. Solid green crosses represent the d50 distribution value (nm). Zeta
potential (C) and PDI (D) data is also included where green and purple crosses represent native and diluted stocks respectively. Error bars represent the ±SEM of the
measurement where n = 5.
The Adju-Phos R© vaccine simulant demonstrated a significant
increase in median particle size relative to the 1 mg/mL Al stock
(P ≤ 0.0001); however, the PSD of the Imject alum R© simulant
remained unaltered (P = 0.16). In addition, introduction into
saline did not influence the PDI of these distributions when data
was compared to that obtained for the respective diluted stocks
(0.18 ± 0.053 and 0.40 ± 0.03, P = 0.90 and 0.32 respectively)
(Figure 2B).
Adjuvant cross-comparisons revealed that particles within
the Adju-Phos R© simulant were significantly larger than those
observed within Alhydrogel R© or Imject alum R© samples
formulated within the same diluent (P = 0.0040 and 0.0004
respectively). No difference was observed between the size of the
latter materials under these conditions (P = 0.39).
All adjuvants maintained the sign of charge exhibited by their
respective native stocks when introduced into saline (Figure 2C).
While the magnitude of the zeta potential values obtained for
both Alhydrogel R© and Imject alum R© significantly increased and
decreased respectively in this diluent (19.33 ± 0.47 and −2.90
± 0.23 mV, P ≤ 0.0001 and 0.008 respectively), no variation in
charge was observed when Adju-Phos R© was exposed to the same
environment (−15.72± 0.26 mV, P= 0.08). Where comparisons
with the 1 mg/mL Al stocks were made, all materials underwent
an increase in the magnitude of their zeta potential. (P = 0.0079,
≤0.0001, and 0.0079 respectively).
The Influence of Protein Adsorption upon
the PSD and Zeta Potential of Aluminum
Adjuvants
The addition of Alhydrogel R© to an isotonic system containing
BSA not only yielded a substantial increase in median size (4194
± 466 nm, P = 0.045) (Figure 3A) but also a dramatic shift in
the value and sign of the adjuvant zeta potential (−6.26 ± 0.06
mV, p ≤ 0.0001) (Figure 3C). This was also accompanied by a
decrease in PDI (0.22± 0.028, P = 0.019) (Figure 3B).
Under the same conditions, the PSD of Adju-Phos R© remained
fairly consistent with the d50 and PDI values showing little
deviation from those obtained in saline (4850± 501 nm and 0.27
± 0.04, P = 0.44 and 0.21 respectively). In this environment the
median size of this adjuvant was similar in magnitude to that
obtained for Alhydrogel R© (P = 0.62). The zeta potential of this
material also underwent a small but significant increase relative
to the vaccine simulant (−13.02± 0.10 mV, p= 0.0002).
The PSD of Imject alum R© was not influenced by the presence
of BSA as demonstrated by the limited variation observed
when the median and PDI values were compared against
diluent only preparations (2155 ± 485 nm and 0.39 ± 0.05,
P = 0.76 and 0.85 respectively); however, the zeta potential
of the material did decrease in magnitude (−5.81 ± 0.14mV,
p ≤ 0.0001).
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FIGURE 2 | Particle size distributions (A), PDI values (B), and zeta potential (C) of aluminum adjuvants prepared in saline to form simulant vaccines containing ca
250 µg/mL Al. Box plots are representative of the interquartile range of the data while red dashed lines indicate the maxima and minima. Solid green crosses
represent the d50 distribution value (nm). Error bars represent the ±SEM of the measurement where n = 5.
Where cross comparisons were performed, protein solutions
containing Imject alum R© generated significantly smaller d50
values than either Alhydrogel R© or Adju-Phos R© formulations
(P = 0.029 and 0.0052 respectively).
The Core Size of Aluminum Adjuvants in
Saline Using TEM
Alhydrogel R© (Figure 4B) presented as a heterogeneous
collection of particulate material where the majority of entities
were between ca 0.8–2 µm in size. These aggregates were
composed of negatively stained primary crystals which were
fibrillar in nature. The tendency of such material to self-associate
and form large, electron dense agglomerates was also apparent as
demonstrated by the presence of a singular structure measuring
ca 8 µm in size.
Adju-Phos R© (Figure 4A) was more homogenous in
composition and was predominantly composed of electron
dense, porous aggregates whose average sizes equated to ca
3 µm. Aggregates were composed of plate-like entities of
approximately 50 nm, although this size was subject to variability
throughout the structure.
Imject alum R© (Figure 4C) was comprised of porous
aggregates which were consistently ca 1 µm in size and
contained two distinct morphologies. The first was composed of
several lamellar like crystals and the second reminiscent of the
platy morphology observed within Adju-Phos R© samples.
DISCUSSION
Following their industrial fabrication, particle size analysis of
adjuvant stocks revealed that a considerable proportion of
material within each sample exceeded the maximum limit of
detection and was thus unable to be accurately measured using
DLS. While this may preclude the derivatization of absolute
size values for these materials, application of this methodology
provides useful insights into the behavior of these materials
in their native environments without the need for further
processing or external interference. The propensity of adjuvant
particles to self-associate and form agglomerated structures
in solution is of particular interest in the study of vaccines
and the presence of such entities within stock suspensions
has been previously confirmed to some extent using sizing
methodologies with a greater upper limit of detection (Burrell
et al., 2000b; Lindblad, 2004; Harris et al., 2012). Indeed, the
median size obtained herein for Adju-Phos R© (7152 ± 308 nm)
is in good agreement with that obtained using low angle laser
light scattering if typical batch variation is also considered (6.2
µm—Kolade et al., 2015), which adds some legitimacy to both
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FIGURE 3 | Particle size distributions (A), PDI values (B), and zeta potential (C) of aluminum adjuvants formulated in saline + BSA (ca 250µg/mL Al). Box plots
are representative of the interquartile range of the data while red dashed lines indicate the maxima and minima. Solid green crosses represent the d50 distribution
value (nm). Error bars represent the ±SEM of the measurement where n = 5.
our native stock adjuvant data and approach to sizing despite its
noted limitations.
Relative cross-comparisons between adjuvants revealed
marked differences between the median size of native materials
and their potential to agglomerate. This tendency toward
agglomeration appeared to be governed by the interaction of
these particles with the surrounding aqueous environment.
Adjuvants whose structures were extensively hydrated i.e.,
Adju-Phos R© and Imject alum R© (Shirodkar et al., 1990; Hem
et al., 2007) yielded the largest median particle size and contained
the highest proportion of entities exceeding ca 9 µm, which
infers that a large amount of particle-solvent interactions may
encourage self-association. The degree of colloidal instability
experienced within these systems was also consistent with their
respective zeta potential readings with the latter being close to
neutrality and as a consequence exhibiting the greatest amount
of sample agglomeration.
Quite conversely, however, the zeta potential of Alhydrogel R©
inferred that the agglomeration potential of this adjuvant
was greater than that of Adju-Phos R©, which was simply not
the case. In fact, this material expressed both the lowest
abundance of agglomerates and the smallest median particle size,
which plausibly may be attributed to its crystalline and less-
hydrated structure (Shirodkar et al., 1990). Furthermore, the high
polydispersity of this sample in particular calls into question
the monomodal nature of its distribution and perhaps gives
a preliminary indication of the existence and contribution of
particulates well in excess of the ca 9 µm maxima. Indeed, other
studies have identified several particulate populations within
colloidal aluminum oxyhydroxide solutions which exceed this
limit including one at 22 µm and another at 44 µm (Wolff
et al., 2008). It follows then that despite its lower d50 and
out of range values, Alhydrogel R© may contain some of the
largest singular agglomerates. There is some evidence to suggest
that the presence of the latter may be related to a lack of
superficial hydrogen bonding within suspension, which has also
been shown to facilitate the nucleation and growth of colloids
(Banfield et al., 2000). When the observations for both the
amorphous and crystalline native adjuvants are considered, such
information implies that an optimal amount of adjuvant-diluent
interactions are required to minimize adjuvant agglomeration, a
characteristic which can negatively impact the efficacy of vaccines
(Maa et al., 2003; Clausi et al., 2008; Braun et al., 2009; Chen et al.,
2009).
The PSD of aluminum adjuvants is also heavily influenced
by dilution, which acts to increase the separation of particles in
solution and thus reduce the likelihood of aggregate formation.
Significant disaggregation was observed within all the colloidal
suspensions studied when the concentration of aluminum was
reduced with the PSD of Adju-Phos R© being the most susceptible
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FIGURE 4 | TEM images of Alhydrogel® (B mag. X30K, scale bar 2 µm), Adju-Phos® (A mag. X10K, scale bar 1 µm), and Imject alum® (C mag. X100K, scale bar
0.2 µm) formulated in 0.9% NaCl.
to these events. This correlated with the concomitant shifts
in adjuvant surface charge toward more negative or positive
values of zeta potential, insinuating that contributions from
repulsive forces were increasing and thus acting to stabilize the
size of particulates. Unlike the mechanical separation induced
by interfacial shear, it remains unclear whether these repulsive
forces are strong enough to maintain stability in the long-
term, especially in the case of Alhydrogel R© and Imject alum R©
whose zeta potential readings highlighted that some degree
of systemic instability was still present within these solutions.
From a biological perspective, reducing the propensity of self-
association through modification of adjuvant dosing may be
beneficial with regards to maximizing particle phagocytosis and
systemic translocation by immune cells. In line with the results
of this study, vaccine simulants prepared using lower doses
of aluminum were shown to contain smaller aggregates than
their more concentrated counterparts and as a consequence
demonstrated an elevated cerebral presence following injection
(Crépeaux et al., 2016).
The vast majority of vaccines are formulated in physiological
saline and contain between 125 and 800 µg/mL Al (Baylor
et al., 2002). In this isotonic environment, whose matrix is
teaming with monovalent electrolytes, charge screening allows
interactive van der Waal forces between adjuvant particles to
predominate, which in theory should facilitate both aggregation
and agglomeration (Derjaguin and Landau, 1941; Verwey and
Overbeek, 1948). Indeed, commercial preparations experienced
varying degrees of aggregation when introduced into this
environment when size comparisons were made with their
respective diluted adjuvant stocks. Surprisingly, these events did
not necessarily correlate with the expected shift in zeta potential
and quite conversely the surface charge of Alhydrogel R© actively
increased in this medium, a trend associated with heightened
contributions from electrostatic repulsion and thus enhanced
colloidal stability.
During the formulation of vaccines, however, it is the
native concentrated stock which is directly mixed with the
diluent and discussing the impact of these events upon the
PSD of aluminum adjuvants is perhaps more relevant in this
context. When mimicked experimentally, the median size of
all materials, exclusive of Alhydrogel R©, underwent a significant
reduction. A dilution of this magnitude did, however, result
in the abolition of the large agglomerates observed within
the native Alhydrogel R© stock. It can therefore be argued that
the removal/disaggregation of these particles also constitutes
a large reduction in particle size and results in an increase
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in systemic stability, which is consistent with the increase in
zeta potential observed. Furthermore, it is clear that when both
dilution and ionic strength are considered within the same
system, it is particulate disaggregation that is favored during
the initial stages of addition and the influence of dilution is
dominates.
The degree to which proteins are adsorbed by aluminum
salts is another factor that governs the size of the particles
found within vaccine preparations. Several studies have reported
substantial adsorption capacities and coefficients for the
Alhydrogel R©/BSA complex while at the same time observing
virtually no adsorption of this protein by Adju-Phos R© (Seeber
et al., 1991; Al-Shakhshir et al., 1994; Jones et al., 2005).
Others have also commented upon the poor antigen adsorption
capacity of Imject alum R© and proposed this as reasoning
for the limited immunological efficacy of this adjuvant in
vivo (Cain et al., 2013). In our study, the masking of native
particle charge observed within Alhydrogel R© model vaccines
inferred that this adjuvant exhibited a high degree of BSA
surface coverage, which can be attributed to the favorable
electrostatic interactions between the protein and adjuvant (Al-
Shakhshir et al., 1994). These results suggest that it was this
degree of protein adsorption that was directly associated with
the significant elevation in particle size observed relative to
the simulant only preparations. In the case of Adju-Phos R©
and Imject alum R©, zeta potential results also suggested that
some adsorption had occurred at the colloidal interface of
these materials. However, due to the small magnitude of these
variations, it is likely that electrostatic repulsion still remained
dominant within these systems, which in all probability severely
restricted protein adsorption. This is consistent with the null
significance observed between the size of these adjuvants in saline
vs. that of the antigen-adjuvant complexes formed in model
vaccines.
The size and consequent recognition of the adjuvant-antigen
complex is thus likely to be dependent on: (i) The species
of protein used as an antigen and (ii) The magnitude of the
association constant between adjuvant and antigen. High affinity
combinations are likely to experience less antigenic elution when
exposed to the physiological milieu at the injection site (Noe
et al., 2010) and thus retain their enhanced size. The latter
may serve to optimize the recognition and uptake of these
complexes as well as delivering a greater amount of antigen
for cellular processing, which in turn improves the kinetics
and efficacy of the immunological response (Mannhalter et al.,
1985). In our recent communication, we demonstrated high
levels of adjuvant loading within the cytoplasm of THP-1 cells
exposed to the Alhydrogel R©-BSA complexes formed through
the exposure of the adjuvant to nutrient rich culture medium
(Mold et al., 2016). This observation was attributed to the large
number of particles falling within the optimal size range for
macrophagic recognition, which is reportedly between 2 and 3
µm (Champion et al., 2008). However, strong associative forces
between adjuvant and antigen can also induce the formation
of agglomerates exceeding 10 µm (Morefield et al., 2005) and
weak adsorption coefficients have been associated with the
generation of higher relative antibody titres (Iyer et al., 2003;
Hansen et al., 2007, 2009; Noe et al., 2010). Such agglomerates
prove challenging to engulf (Morefield et al., 2005; Mold et al.,
2016) and their subsequent cellular translocation to the lymph
nodes may be significantly impeded as a result. In addition,
conformational changes induced upon the adsorption of protein
are more frequently encountered at the low concentrations
of antigen used herein and in clinical vaccines (Lassen and
Malmsten, 1996; Rabe et al., 2011). These alterations in protein
structure have been linked to a decrease in particle-cellular
adhesion and a subsequent reduction in their internalization
by phagocytes (Yan et al., 2013); however, similar patterns of
behavior have not yet been observed in the case of aluminum
salts.
As alluded to at the beginning of this discussion, it is
acknowledged that the limitations of DLS make the accurate
characterization of polydisperse and agglomerated solutions
challenging. The random movement of particles within highly
concentrated solutions can be severely restricted and the intensity
based nature of the measurements precludes the objective
analysis of sample diversity. The latter was observed through the
complementary use of microscopy but this technique requires
conditions which are non-hydrodynamic and as a consequence
particulate dimensions are comparatively smaller. It is thus
not unreasonable to suggest that the biological reactivity of
these materials will be more dependent on the abundance
of these discrete populations, which may also include the
presence of metal ions. Future studies will therefore focus
upon the characterization and quantification of these individual
populations in order to establish their relative physiological
impact.
CONCLUSION
While interest in the physicochemical characterization of
aluminum salts has waned over recent years, such studies
are crucial with regards to the development of safer and
more effective vaccines. The link between particle size and
immunopotentiation, although conflicting, has been widely
established (Xiang et al., 2006; Oyewumi et al., 2010) but still
there remains a limited body of work in this area specifically
relating to aluminum adjuvants. To this effect, this is the first
study to directly monitor the hydrodynamic PSD of a variety
of aluminum-based adjuvants over the systematic stages of
vaccine preparation. We have shown herein that the particle size
of aluminum salts is heavily influenced by the concentration
of aluminum and degree of protein adsorption experienced
within the vaccine preparation itself during the formulation
process. More importantly, it is likely that the resultant size of
these antigen-adjuvant complexes will in some way dictate their
subsequent recognition and translocation by components of the
immune system.
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